ObjectiveTo observe the efficacy of butylphthalide combined with alteplase intravenous thrombolysis in treating patients with acute cerebral infarction (ACI) and its effect on neurotransmitter level and nerve function. MethodsA total of 78 patients with ACI hospitalized in our hospital from January 2017 to June 2019 were selected as the research objects, and were divided into control group and observation group by random number method, with 39 cases in each group. The control group was given alteplase thrombolytic therapy, and the observation group was treated with alteplase combined with butylphthalide, for two-week continuous treatment in both groups. The clinical efficacy, blood dopamine and serotonin levels, Barthel index (BI) scores, and incidence of adverse reactions were compared between the two groups. ResultsThe total effective rate of treatment in the observation group was significantly higher than that in the control group (94.87% vs. 76.92%), and the clinical efficacy was superior to that in the control group, with statistically significant differences (P＜0.05). There were no statistically significant differences in dopamine, serotonin levels and BI scores between the two groups before treatment (P＞0.05). After 2 weeks of treatment, the levels of dopamine and serotonin, as well as BI scores in the observation group were higher than those in the control group, with statistically significant differences (P＜0.05). During treatment, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionButylphthalide combined with alteplase intravenous thrombolysis has a definite clinical effect in ACI, with high safety of treatment, which can significantly increase the level of neurotransmitter, improve nerve function, and thus improve self-care ability of daily living in patients.

无